Indian lifesciences sector eyeing long-term capital to accelerate biologics, plasma-derived therapies

Indian lifesciences sector is increasingly looking at long-term capital to accelerate the expansion of its biologics and plasma-derived therapies. This is because healthcare demands advanced treatments resulting in the

To access the full article, please log in or subscribe.